Q: ESSA Pharma is just one example of an exciting pharma in a topically interesting (prostate cancer, aging population…) area but with impenetrable valuation characteristics. Can you say whether this stock’s prospects are worth its price? Are there other early-stage pharmas you like?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: I’d appreciate your thoughts on the healthcare company Certara (CERT).